225 related articles for article (PubMed ID: 35704272)
1. Therapeutic Potential of Histamine H3 Receptors in Substance Use Disorders.
Di Ciano P; Hendershot CS; Le Foll B
Curr Top Behav Neurosci; 2022; 59():169-191. PubMed ID: 35704272
[TBL] [Abstract][Full Text] [Related]
2. Effects of histamine H3 receptor ligands on the rewarding, stimulant and motor-impairing effects of ethanol in DBA/2J mice.
Nuutinen S; Vanhanen J; Pigni MC; Panula P
Neuropharmacology; 2011 Jun; 60(7-8):1193-9. PubMed ID: 21044640
[TBL] [Abstract][Full Text] [Related]
3. Evidence for the role of histamine H3 receptor in alcohol consumption and alcohol reward in mice.
Nuutinen S; Lintunen M; Vanhanen J; Ojala T; Rozov S; Panula P
Neuropsychopharmacology; 2011 Sep; 36(10):2030-40. PubMed ID: 21654737
[TBL] [Abstract][Full Text] [Related]
4. Histamine H3 receptor antagonist decreases cue-induced alcohol reinstatement in mice.
Nuutinen S; Mäki T; Rozov S; Bäckström P; Hyytiä P; Piepponen P; Panula P
Neuropharmacology; 2016 Jul; 106():156-63. PubMed ID: 26107118
[TBL] [Abstract][Full Text] [Related]
5. Histamine H3 receptor antagonist JNJ-39220675 modulates locomotor responses but not place conditioning by dopaminergic drugs.
Vanhanen J; Kinnunen M; Nuutinen S; Panula P
Psychopharmacology (Berl); 2015 Mar; 232(6):1143-53. PubMed ID: 25308376
[TBL] [Abstract][Full Text] [Related]
6. Histamine H3 receptor antagonists - Roles in neurological and endocrine diseases and diabetes mellitus.
Abdulrazzaq YM; Bastaki SMA; Adeghate E
Biomed Pharmacother; 2022 Jun; 150():112947. PubMed ID: 35447544
[TBL] [Abstract][Full Text] [Related]
7. The novel non-imidazole histamine H3 receptor antagonist DL77 reduces voluntary alcohol intake and ethanol-induced conditioned place preference in mice.
Bahi A; Sadek B; Nurulain SM; Łażewska D; Kieć-Kononowicz K
Physiol Behav; 2015 Nov; 151():189-97. PubMed ID: 26169446
[TBL] [Abstract][Full Text] [Related]
8. Progress in the development of histamine H
Łażewska D; Kieć-Kononowicz K
Expert Opin Ther Pat; 2018 Mar; 28(3):175-196. PubMed ID: 29334795
[TBL] [Abstract][Full Text] [Related]
9. Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol.
Krief S; Berrebi-Bertrand I; Nagmar I; Giret M; Belliard S; Perrin D; Uguen M; Robert P; Lecomte JM; Schwartz JC; Finance O; Ligneau X
Pharmacol Res Perspect; 2021 Oct; 9(5):e00855. PubMed ID: 34423920
[TBL] [Abstract][Full Text] [Related]
10. Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects.
Esbenshade TA; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Fox GB; Faghih R; Bennani YL; Williams M; Hancock AA
J Pharmacol Exp Ther; 2003 Jun; 305(3):887-96. PubMed ID: 12606603
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in molecular pharmacology of the histamine systems: physiology and pharmacology of histamine H3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders.
Tokita S; Takahashi K; Kotani H
J Pharmacol Sci; 2006 May; 101(1):12-8. PubMed ID: 16648667
[TBL] [Abstract][Full Text] [Related]
12. The histamine H3 receptor: an attractive target for the treatment of cognitive disorders.
Esbenshade TA; Browman KE; Bitner RS; Strakhova M; Cowart MD; Brioni JD
Br J Pharmacol; 2008 Jul; 154(6):1166-81. PubMed ID: 18469850
[TBL] [Abstract][Full Text] [Related]
13. Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists.
Le S; Gruner JA; Mathiasen JR; Marino MJ; Schaffhauser H
J Pharmacol Exp Ther; 2008 Jun; 325(3):902-9. PubMed ID: 18305012
[TBL] [Abstract][Full Text] [Related]
14. Histamine H3 receptor activation prevents dopamine D1 receptor-mediated inhibition of dopamine release in the rat striatum: a microdialysis study.
Alfaro-Rodriguez A; Alonso-Spilsbury M; Arch-Tirado E; Gonzalez-Pina R; Arias-Montaño JA; Bueno-Nava A
Neurosci Lett; 2013 Sep; 552():5-9. PubMed ID: 23896530
[TBL] [Abstract][Full Text] [Related]
15. New developments around histamine H(3) receptor antagonists/inverse agonists: a patent review (2010 - present).
Łażewska D; Kieć-Kononowicz K
Expert Opin Ther Pat; 2014 Jan; 24(1):89-111. PubMed ID: 24131059
[TBL] [Abstract][Full Text] [Related]
16. Influence of the novel histamine H₃ receptor antagonist ST1283 on voluntary alcohol consumption and ethanol-induced place preference in mice.
Bahi A; Sadek B; Schwed SJ; Walter M; Stark H
Psychopharmacology (Berl); 2013 Jul; 228(1):85-95. PubMed ID: 23474889
[TBL] [Abstract][Full Text] [Related]
17. Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs.
Zhang M; Ballard ME; Pan L; Roberts S; Faghih R; Cowart M; Esbenshade TA; Fox GB; Decker MW; Hancock AA; Rueter LE
Brain Res; 2005 May; 1045(1-2):142-9. PubMed ID: 15910772
[TBL] [Abstract][Full Text] [Related]
18. Autoregulation of McA-RH7777 hepatoma cell proliferation by histamine H3 receptors.
Davenas E; Rouleau A; Morisset S; Arrang JM
J Pharmacol Exp Ther; 2008 Aug; 326(2):406-13. PubMed ID: 18474684
[TBL] [Abstract][Full Text] [Related]
19. Anticonvulsant properties of histamine H3 receptor ligands belonging to N-substituted carbamates of imidazopropanol.
Sadek B; Shehab S; Więcek M; Subramanian D; Shafiullah M; Kieć-Kononowicz K; Adem A
Bioorg Med Chem Lett; 2013 Sep; 23(17):4886-91. PubMed ID: 23891186
[TBL] [Abstract][Full Text] [Related]
20. Structural modifications in the distal, regulatory region of histamine H
Szczepańska K; Pockes S; Podlewska S; Höring C; Mika K; Latacz G; Bednarski M; Siwek A; Karcz T; Nagl M; Bresinsky M; Mönnich D; Seibel U; Kuder KJ; Kotańska M; Stark H; Elz S; Kieć-Kononowicz K
Eur J Med Chem; 2021 Mar; 213():113041. PubMed ID: 33261900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
